NAD Treatment Center offers a cutting-edge neuromodulator called the BRIDGE to support clients during the opiate withdrawal process. Currently, Dr. Milgram is the only certified provider in Southern California able to offer the BRIDGE. Since it is designed to be used in association with physician-guided programs, Dr. Milgram employs this technology as part of a revolutionary therapy called The NAD Treatment Center Detox Method.

What is the BRIDGE?

Pain associated with the withdrawal process can be debilitating and in some cases, a major deterrent to detox. With the BRIDGE device, withdrawal pain and the fear of pain, are no longer obstacles to recovery. The BRIDGE is an FDA-cleared device that helps target the pain and discomfort patients can experience during withdrawal specifically from opioids.

How does the BRIDGE work?

Pioneered by Innovative Health Solutions, the BRIDGE is a peripheral nerve stimulator that attaches behind the ear and sends gentle electrical impulses directly into the brain, blocking pain signals. A trained provider implants the device and its electrodes just behind the ear, where the cranial nerves are closest to the surface. A battery-operated chip sends impulses to nerves to block the pain.

What makes the BRIDGE so unique?

The BRIDGE is a safe, effective and evidence-based alternative to pain management for opiate withdrawal. It is the ideal therapy for the pain associated with withdrawal from heroin, Suboxone, methadone, oxymorphone and opiate pills, such as hydrocodone, oxycodone, and fentanyl. The device is meant as a short-term solution to pain management and should be used in conjunction with other therapuetic methods, such as The NAD Treatment Center Detox Method, for long-term recovery success.

Some of the key advantages include:

  • Non-narcotic
  • Non-addictive
  • Reduction of pain within 30-60 minutes (sometimes even 10 minutes)
  • No incision or anesthesia required
  • No radiation exposure
  • No side effects

Effects of BRIDGE on Opioid Withdrawal Scores





These statements have not been evaluated by the Food and Drug Administration. The Bridge and intravenous NAD+ therapy is not intended to diagnose, treat, cure, or prevent any disease.